← All trials
NCT04713657
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Feb 1, 2025
- Completion date
- Aug 1, 2025
- First posted
- Jan 19, 2021
- Last posted
- Aug 17, 2021
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PittsburghLead sponsor
- University of PittsburghSponsor investigator
- University of PittsburghCollaborator
- University of PittsburghOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.